Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Abstract Background Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. Methods This phase 2, randomized, open-label, parallel-group exten...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Yutaka Osuga, Yoshifumi Seki, Masataka Tanimoto, Takeru Kusumoto, Kentarou Kudou, Naoki Terakawa
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2021-06-01
Schriftenreihe:	BMC Women's Health
Schlagworte:	Relugolix Endometriosis Leuprorelin acetate Extension study Gonadotropin-releasing hormone antagonist
Online-Zugang:	https://doi.org/10.1186/s12905-021-01393-3
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!